BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 11050888)

  • 1. [Insulin sensitizer. A new therapy option for type 2 diabetic patients].
    Filz HP
    MMW Fortschr Med; 2000 Sep; 142(38):31-3. PubMed ID: 11050888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
    Krentz AJ; Bailey CJ; Melander A
    BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
    [No Abstract]   [Full Text] [Related]  

  • 3. Differentiating members of the thiazolidinedione class: a focus on efficacy.
    Goldstein BJ
    Diabetes Metab Res Rev; 2002; 18 Suppl 2():S16-22. PubMed ID: 11921434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin resistance and its treatment by thiazolidinediones.
    Lebovitz HE; Banerji MA
    Recent Prog Horm Res; 2001; 56():265-94. PubMed ID: 11237217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The glitazones: proceed with caution.
    Krische D
    West J Med; 2000 Jul; 173(1):54-7. PubMed ID: 10903299
    [No Abstract]   [Full Text] [Related]  

  • 6. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
    Scheen AJ; Lefèbvre PJ
    Diabetes Care; 1999 Sep; 22(9):1568-77. PubMed ID: 10480527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Troglitazone and related compounds: therapeutic potential beyond diabetes.
    Fujiwara T; Horikoshi H
    Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
    Ohmura E; Hosaka D; Imai Y; Kawazu S
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
    [No Abstract]   [Full Text] [Related]  

  • 9. [Thiazolidinediones: clinical data and perspectives].
    Blicklé JF
    Diabetes Metab; 2001 Apr; 27(2 Pt 2):279-85. PubMed ID: 11452222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
    Brogard JM; Neyrolles N; Andres E; Blicklé JF
    Rev Med Interne; 1999 Aug; 20 Suppl 3():371s-378s. PubMed ID: 10480188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glitazones: clinical effects and molecular mechanisms.
    Stumvoll M; Häring HU
    Ann Med; 2002; 34(3):217-24. PubMed ID: 12173692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troglitazone in type II diabetes mellitus.
    Sparano N; Seaton TL
    Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity with thiazolidinediones: is it a class effect?
    Scheen AJ
    Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
    Khan MA; St Peter JV; Xue JL
    Diabetes Care; 2002 Apr; 25(4):708-11. PubMed ID: 11919129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
    Blonde L; Sandberg MI; Guthrie RD
    Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
    [No Abstract]   [Full Text] [Related]  

  • 16. Repaglinide in combination therapy.
    Moses R
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
    Plosker GL; Faulds D
    Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.
    Gavin LA; Barth J; Arnold D; Shaw R
    Endocr Pract; 2000; 6(4):305-10. PubMed ID: 11242607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus.
    Parker JC
    Adv Drug Deliv Rev; 2002 Nov; 54(9):1173-97. PubMed ID: 12393300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New diabetes drug targets insulin resistance.
    Am J Health Syst Pharm; 1997 Mar; 54(6):623, 625. PubMed ID: 9075488
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.